Sudarshan Publications

Available online at https://s-epub.in/index.php/trp/index

Pharma Research

An International Peer Reviewed, Indexed Journal

10.62655/s-epub.2021.v13.i02.pp71-78

MICROWAVE-ASSISTED SYNTHESIS OF QUINAZOLINONE DERIVATIVES AS POTENTIAL ANTICONVULSANT AGENTS

ELODIE MORVAN[1]*, TOMASZ PAWLAK[2], CHIARA CAVALIERI[3]

Affiliation

[1]Department of Organic Chemistry, Loire Valley Institute of Pharmacy, Saumur, France
[2]Department of Organic Chemistry, Warmia Institute of Pharmaceutical Sciences, Olsztyn, Poland
[3]Department of Pharmaceutical Chemistry, Cilento Institute of Pharmaceutical Sciences, Salerno, Italy

*Corresponding author: Elodie Morvan, e.morvan@lvip.fr
ORCID iD: Elodie Morvan 0000-0001-3995-8636; Tomasz Pawlak 0000-0001-2301-3873; Chiara Cavalieri 0000-0001-3959-9581

Article info

Received date:30-05-2021
Accepted date:06-09-2021
Published date:22-12-2021
ISSN;0975-8216

Keywords:

Quinazolinone, Microwave synthesis, Anticonvulsant, Epilepsy, Green chemistry

Abstract

Quinazolin-4(3H)-ones have been explored as anticonvulsant scaffolds since the methaqualone era, and microwave heating has changed how many of them are made. This review draws on published chemistry and pharmacology to describe how microwave irradiation is applied to quinazolinone construction, how the resulting compounds are screened in standard rodent seizure models, and what structure-activity trends have been reported. Shorter reaction times, cleaner conversions and reduced solvent use are the recurring advantages, although claims of special non-thermal effects remain contested. Pharmacological reports rely on a narrow set of acute screens and rarely address mechanism or pharmacokinetics. This is a narrative review and reports no new experimental data.

1. INTRODUCTION

Epilepsy is a chronic disorder of the brain defined by an enduring tendency to generate unprovoked seizures [1]. Most people respond to the first or second antiepileptic drug they are given, yet about a third continue to have seizures despite adequate trials of two or more agents [2, 3]. That figure has barely moved, even though many new drugs have reached the market over the past three decades [4, 5]. The burden of treatment failure falls hardest on people with frequent seizures, who face injury, cognitive decline and reduced quality of life.

The persistent gap has kept medicinal chemists interested in scaffolds that can be modified quickly and tested cheaply. Quinazolin-4(3H)-one is one of them. It is a fused benzene and pyrimidinone ring system,

easy to substitute at the 2 and 3 positions, and it appears in a long list of bioactive molecules [6, 7, 8]. Methaqualone, a 2,3-disubstituted member of the family, was used as a sedative-hypnotic and showed anticonvulsant behaviour in animals, which is why the scaffold keeps returning to anticonvulsant programmes [6, 9].

Tolerability is the second driver. Existing drugs are effective for many patients but carry dose-related adverse effects, including drowsiness, dizziness, ataxia and cognitive slowing, and some produce idiosyncratic reactions or interact with other medicines through enzyme induction [4, 10]. A newer agent that matched the efficacy of established drugs while sparing the sedative burden would still count as progress, even if it did nothing for refractory disease. Quinazolinones carry a historical association with sedation, so any programme built on them has to show, early and convincingly, that anticonvulsant activity can be separated from central depression [5, 11].

Synthesis speed is the practical bottleneck in such programmes. Conventional quinazolinone preparations often need several hours of reflux, high-boiling solvents and tedious work-up. Microwave-assisted organic synthesis offers a way round this, and it has become routine in medicinal chemistry laboratories since commercial reactors with temperature and pressure control became available [12, 13]. This review brings the two threads together: how microwave methods are used to build quinazolinones, how the products are evaluated for anticonvulsant activity, what trends are reported, and where the evidence is weak.

A note on scope is needed. The article reports no new synthetic or pharmacological data. It summarises what other groups have published, and where numerical claims appear they are described qualitatively unless they are widely quoted.

2. QUINAZOLINONE CHEMISTRY

The quinazoline nucleus was first characterised in the nineteenth century, and the chemistry of the oxidised 4(3H)-one forms was systematised in the following decades [14]. Extensive reviews now catalogue the ring-forming reactions, the reactivity of each position and the biological activities reported, which range from anticancer and antimicrobial to anti-inflammatory and central nervous system effects [6, 7, 8, 15]. The breadth of that literature is itself a warning. A scaffold that appears active everywhere may simply be a convenient one to publish on. Reviews of this type are useful for orientation, but they seldom weigh the quality of the primary evidence behind each activity claim [6, 8, 15].

Most routes start from anthranilic acid or one of its derivatives. Acylation of the amine, cyclisation through a benzoxazinone intermediate, and reaction of that intermediate with a primary amine or hydrazine gives 2,3-disubstituted quinazolin-4(3H)-ones. Alternatively, anthranilic acid is heated directly with an amide in the Niementowski reaction, a one-pot condensation that works but traditionally demands temperatures around 130 to 150 °C for hours [7, 14, 16]. Isatoic anhydride, 2-aminobenzamide and 2-aminobenzonitrile are other common starting points [6, 7].

Structural detail is more slippery than the drawings in papers suggest. Quinazolin-4(3H)-ones with an unsubstituted N-3 exist as lactam and lactim tautomers, and alkylation can occur at nitrogen or oxygen depending on base, solvent and electrophile. Assignments are usually made from NMR shifts of the new $N\text{-}CH_2$ or $O\text{-}CH_2$ signals and occasionally confirmed by crystallography [6, 7]. Where authors simply assume N-alkylation, a fraction of the biological data in the literature may refer to a different isomer than the one named. That is rarely discussed, but it matters when structure-activity trends are being drawn.

Late-stage diversification has widened the chemical space. Besides the classical cyclocondensations, published methods include transition-metal-catalysed carbonylation and amination of 2-haloanilines or 2-halobenzamides, oxidative cyclisations of 2-aminobenzamides with aldehydes or alcohols, and multicomponent reactions that assemble the ring and its substituents in a single vessel [6, 7, 8]. Several of these are attractive for library synthesis, yet most

anticonvulsant studies still use the older benzoxazinone or Niementowski chemistry, probably because the starting materials are cheap and the reactions forgiving. A gap between what synthetic chemists can make and what pharmacologists actually test is evident [6, 15].

Substitution at the 2 and 3 positions matters most for central nervous system activity. A small alkyl or aryl group at C-2 and an aryl or heteroaryl group at N-3 characterise many of the compounds that protected animals in seizure tests [9, 17, 18]. The benzo ring, particularly the 6 and 7 positions, is varied less often, which leaves an obvious area unexplored.

3. MICROWAVE HEATING IN SYNTHESIS

Microwave heating entered organic chemistry in the mid-1980s, when two groups reported that ordinary domestic ovens could speed up esterification, hydrolysis and other reactions [19, 20]. Those early experiments used sealed vessels in unmodified ovens and were hard to reproduce. Purpose-built single-mode and multimode reactors changed that, with fibre-optic or infrared temperature sensing, pressure monitoring and stirring [12, 21]. Within a decade the technique had moved from curiosity to routine bench equipment in many pharmaceutical laboratories [13].

The mechanism of heating is dielectric. Polar molecules and ions try to align with the oscillating electric field, and the resulting friction and conduction losses heat the mixture from within instead of through the vessel wall [21, 22]. Solvents with high loss tangents, such as dimethylformamide, ethanol and water at elevated temperature, absorb strongly. Hexane and toluene barely couple at all. The practical consequence is that a closed vessel can be taken well above the normal boiling point of its solvent within seconds, and Arrhenius behaviour then accounts for most of the speed-up.

Whether anything beyond bulk heating is going on has been argued for two decades. Some authors invoked specific or non-thermal microwave effects, such as selective heating of catalysts or stabilisation of polar transition states [22, 23]. Careful comparisons with identical temperature profiles have often found no difference in outcome, and a mechanistic analysis concluded that claims of specific rate enhancement need much stronger evidence than most reports provide [24]. Hot spots and superheating are probably the usual explanation for apparent anomalies.

Practical choices follow from the physics. Sealed borosilicate or quartz vessels tolerate pressures of roughly 20 bar in most commercial instruments, and volatile reagents such as ammonia, low-boiling amines or formamide decomposition products can generate more pressure than expected [12, 13]. Stirring matters, because uneven heating is one cause of poor reproducibility. Power settings alone are a poor descriptor of an experiment, and good reports state the target temperature, ramp time, hold time and vessel type. Many older microwave quinazolinone papers give only a wattage and a time, which makes them hard to repeat on another instrument [12, 21].

4. MICROWAVE ROUTES TO QUINAZOLINONES

The Niementowski reaction was one of the first quinazolinone syntheses to be revisited under microwave irradiation. Anthranilic acids and formamide or acetamide, heated in an open or sealed vessel, gave the parent ring system in minutes rather than hours, with comparable or better yields than conventional heating [16]. The report is often cited because it showed an old name reaction could be revived without any change in chemistry, only in how energy was delivered.

Since then the range of microwave quinazolinone methods has widened. Reported procedures include two-step benzoxazinone routes in which cyclisation and amine condensation are each shortened to a few minutes, three-component condensations of isatoic anhydride, an amine and an orthoester or aldehyde, and metal-catalysed couplings that build the ring from 2-halobenzamides [6, 7, 8]. The summary in table 1 groups representative findings from the literature by theme, covering scaffold series, synthetic methods and the screening models used to test them

(fig. 1).

Typical conditions illustrate the saving. Conventional preparations of 2,3-disubstituted quinazolinones from a benzoxazinone and an amine are commonly refluxed for several hours in ethanol, acetic acid or pyridine. Under microwave heating at 120 to 160 °C, the same transformations are reported to finish within roughly 5 to 30 minutes, and isolated yields are described as similar or modestly higher [7, 8, 16]. Acid catalysts and Lewis acids are sometimes added, though several procedures work without them. The more convincing papers run the conventional reaction in parallel at the same temperature in a sealed tube, which separates the effect of the vessel from the effect of the irradiation [22, 24]. Reaction mass efficiency is seldom calculated.

Table 1: Representative published findings on quinazolinone anticonvulsants and their microwave synthesis

Topic	Reported finding	Ref.
Methaqualone-type 2,3-disubstituted quinazolinones Prototype series	Sedative-hypnotic with anticonvulsant behaviour in animals; the starting point for later 2-substituted 3-aryl analogues.	[6, 9]
2-Substituted 3-aryl analogues	Activity in electroshock testing depended on the 3-aryl substituent; small lipophilic groups were favoured over polar ones.	[9]
Thiadiazolyl and thiazolidinonyl derivatives	Protection reported in electroshock and pentylenetetrazole screens with limited motor impairment.	[17, 18]
Urea-linked 3-substituted derivatives	Anticonvulsant activity with CNS depressant effects reported alongside; mechanism not established.	[25]
Microwave Niementowski reaction	Anthranilic acid and amides condense in minutes rather than hours with comparable yields.	[16]
Controlled single-mode reactors	Temperature and pressure monitoring gives reproducible conditions and rapid library preparation.	[12, 13, 21]
Solvent-free solid-supported reactions	Lower solvent use; yields and scale-up vary between substrates.	[26, 27]
Maximal electroshock test	Detects prevention of seizure spread; predictive for generalised tonic-clonic and focal seizures.	[28, 29]
Subcutaneous pentylenetetrazole test	Detects raised seizure threshold; linked to absence and myoclonic seizure activity.	[29, 30]
Rotarod neurotoxicity assessment	Estimates motor impairment so that a protective index can be calculated.	[29, 30]
6 Hz and kindling models	Harder tests used to identify agents for pharmacoresistant epilepsy; rarely applied to quinazolinones.	[31, 32]




Fig. 1: Number of entries in table 1 by theme

Catalyst-assisted microwave variants are worth separating from catalyst-free ones. Palladium and copper systems accelerate carbon-nitrogen bond formation under irradiation and allow substituents to be introduced that are inaccessible by condensation alone, but they bring the issue of metal residues, which matters for any compound destined for biological testing [7, 8, 13]. Where the ring is built without metals, simple acid or base mediation is generally enough. The choice therefore trades synthetic reach against purification burden, and papers that aim at pharmacological evaluation tend to favour the metal-free option for that reason [6, 13].

Solvent-free and solid-supported variants deserve a mention because they connect the technique to green chemistry. Reagents adsorbed onto alumina, silica or clay absorb microwaves differently from the bulk, and the absence of solvent removes both a cost and a disposal problem [26, 27]. Yields are not always better. Scale-up is also a recognised difficulty, since penetration depth of

microwaves in a large batch is only a few centimetres in polar media, and most published procedures involve milligram to low gram quantities [12, 13].

5. ANTICONVULSANT EVALUATION

Almost all quinazolinone anticonvulsant papers use the same small battery of acute tests developed through the US National Institutes of Health programme [29, 30]. The maximal electroshock test, introduced in the 1950s, identifies compounds that prevent spread of tonic hindlimb extension and correlates with efficacy against generalised tonic-clonic and focal seizures in people [28, 29]. The subcutaneous pentylenetetrazole test detects drugs that raise seizure threshold, a pattern linked to activity against absence and myoclonic seizures [29, 30]. A rotarod or similar motor test estimates neurotoxicity so that protective index can be calculated.

Dose selection and timing are part of the design. A standard first pass tests each compound at a few fixed doses, for example 30, 100 and 300 mg/kg, and reads protection at an early time point to catch rapidly acting compounds and a later one to catch slower or longer-lasting ones [29, 30]. Compounds that protect at the lowest dose are moved on to quantal dose-response studies so that an ED_{50}, a median toxic dose and a protective index can be calculated. The sequence is efficient, and it explains why so many papers end at the stage of a single-dose table. Without the second step, neither potency nor margin of safety can be compared with established drugs [28, 29].

Animal welfare and statistical power also deserve attention. Studies with four animals per group cannot distinguish partial from full protection with any confidence, and a result such as three of four animals protected carries wide uncertainty. Journals and funders increasingly expect randomisation, blinding of the observer and justification of group sizes, and the NIH screening programmes have standardised protocols partly to reduce between-laboratory noise [30, 31, 32]. Chemistry groups that collaborate with an established screening centre therefore produce data that other workers find easier to trust than data from ad hoc in-house assays [31].

These screens have a good track record at finding phenytoin-like and carbamazepine-like drugs. They have a poor track record at finding drugs for pharmacoresistant epilepsy, and several authors have argued that continued reliance on them is part of the reason the proportion of refractory patients has not fallen [4, 5, 32]. Models using kindled animals, 6 Hz stimulation at higher current, or chronic spontaneous seizures after status epilepticus are more demanding and more expensive, and the NINDS Epilepsy Therapy Screening Program was set up partly to make them more accessible [31, 32].

Reporting conventions also limit comparison. Doses are often given as single intraperitoneal values at 30 minutes and 4 hours, with protection recorded as a fraction of animals in a group of four to six. Different laboratories use different vehicles, mouse strains and cut-offs. Reference drugs such as phenytoin, carbamazepine and sodium valproate are included, but the comparison is rarely accompanied by dose-response data, so an ED_{50} is the exception [9, 18, 25].

Drug-likeness deserves attention before any animal is dosed. Orally active central nervous system drugs sit in a narrower property window than drugs in general, with molecular weight mostly under about 450, few hydrogen-bond donors and a polar surface area that keeps passive penetration of the blood-brain barrier feasible [33, 34]. Quinazolinones carrying several amide or urea groups can drift outside that window, and a compound that is potent in vitro or after intraperitoneal injection may never reach the brain at a useful concentration when given orally [33, 34]. Few anticonvulsant quinazolinone papers report calculated properties, let alone measured permeability or plasma and brain levels.

6. STRUCTURE-ACTIVITY AND MECHANISM

Across the published series some patterns recur. Wolfe and colleagues found that 2-substituted 3-aryl quinazolinones retained anticonvulsant activity when the aryl ring carried small lipophilic or

electron-withdrawing substituents, while polar groups tended to reduce it [9]. Later work added heterocyclic appendages at N-3, including thiadiazole and thiazolidinone rings, and reported protection in electroshock and pentylenetetrazole screens with limited neurotoxicity [17, 18]. Urea-linked derivatives gave a similar picture [25]. Such gaps are worth stating plainly.

The pharmacophore models commonly invoked for anticonvulsants, with a hydrophobic aryl unit, a hydrogen-bonding domain and an electron-donor group, fit many quinazolinones reasonably well, and this is the usual rationale for the substituents chosen [17, 18, 25]. The fit is descriptive rather than predictive. Few papers test whether a given analogue actually binds the proposed target.

Lipophilicity appears to be a recurring theme. In several series, activity rose with the introduction of halogens, methyl or methoxy groups on the pendant aryl ring and fell with polar substituents such as hydroxyl or carboxyl groups, which fits the requirement for brain penetration [9, 18, 33]. Substituents on the quinazolinone benzo ring, notably 6-halo and 6,8-dihalo patterns, have been used to modulate activity and metabolic stability, although direct matched-pair comparisons are uncommon [17, 25]. Hybrid molecules joining the quinazolinone to another recognised anticonvulsant fragment are popular, but the additive logic behind them has seldom been tested against the separate fragments [15, 17].

Mechanistic claims are therefore tentative. Methaqualone itself is thought to act at the $GABA_A$ receptor, and positive modulation of GABA-mediated inhibition has been suggested for other quinazolinones, though binding studies are scarce [9, 10, 35]. Other antiepileptic mechanisms, namely blockade of voltage-gated sodium channels, reduction of excitatory glutamate transmission and effects on calcium channels, are plausible but rarely examined for this class [10, 11]. The shape of the screening results, with electroshock activity more common than pentylenetetrazole activity in several series, would be consistent with sodium channel effects, but that remains inference.

7. LIMITATIONS AND FUTURE DIRECTIONS

Several weaknesses run through this literature. Biological data are mostly single-dose and qualitative, positive results outnumber negative ones to an implausible degree, and compounds are seldom resynthesised or independently retested. Chemistry papers and pharmacology papers are frequently written by different groups, so the link between synthetic efficiency and biological value is rarely examined. A microwave route that saves four hours at the bench does not make a compound a better drug [13, 24].

Translation is the final hurdle. Activity in a mouse electroshock screen is a long way from a clinical candidate, and the history of antiepileptic drug development shows that most compounds fail on pharmacokinetics, toxicity or lack of efficacy in refractory patients, not on early potency [4, 5]. Programmes that start from an old scaffold also face novelty questions, since patent space around quinazolinones is crowded. Honest reporting of which screens a compound failed, and how it compares with established drugs at equivalent doses, would help reviewers and funders judge which series deserve further investment [31, 32].

Better practice is not complicated. Compounds should be characterised and purity-checked to a standard suitable for biological testing, tested over a dose range in more than one model including at least one pharmacoresistant model, and profiled early for metabolic stability and brain exposure [31, 32, 34]. Mechanistic work, for instance receptor binding or patch-clamp recordings, would turn descriptive series into testable hypotheses [10, 11, 35].

Interpretation of biological claims needs the same care applied to chemistry. Activity at a single dose in one test does not establish an anticonvulsant, and the common practice of describing compounds as potent on that basis overstates the evidence [4, 5, 29]. Phrases such as promising or potential anticonvulsant are best reserved for compounds with a measured ED_{50}, a protective index and activity in more than one model. Applying that threshold would shorten many reference

lists and make the remaining claims more credible.

8. CONCLUSION

Quinazolinones remain a reasonable scaffold for anticonvulsant exploration, and microwave irradiation has made their preparation faster, more reproducible and often cleaner [12, 13, 16]. The synthetic advantage is real. The case for a distinct microwave effect on chemistry is weaker, and the benefits are best described as efficient and controllable heating [24].

The pharmacological side of the literature is thinner than the chemistry. Acute rodent screens dominate, dose-response and mechanism are uncommon, and few series have been tested in models of pharmacoresistant seizures [4, 5, 31, 32]. Closing those gaps, along with fuller reporting of purity and brain exposure, would do more for the field than additional analogues made faster.

9. ABBREVIATIONS

ED_{50}-Median effective dose, GABA-Gamma-aminobutyric acid, NINDS-National Institute of Neurological Disorders and Stroke, NMR-Nuclear magnetic resonance, CNS-Central nervous system, MES-Maximal electroshock, PTZ-Pentylenetetrazole

10. FUNDING

Nil

11. AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

12. CONFLICT OF INTERESTS

Declared none

13. REFERENCES

1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, *et al.* ILAE official report: a practical clinical definition of epilepsy. Epilepsia 2014;55:475–82.
2. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314–9.
3. Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;78:1548–54.
4. Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011;52:657–78.
5. Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 2013;12:757–76.
6. Khan I, Ibrar A, Abbas N, Saeed A. Recent advances in the structural library of functionalized quinazoline and quinazolinone scaffolds: synthetic approaches and multifarious applications. Eur J Med Chem 2014;76:193–244.
7. Connolly DJ, Cusack D, O'Sullivan TP, Guiry PJ. Synthesis of quinazolinones and quinazolines. Tetrahedron 2005;61:10153–202.
8. Asif M. Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives. Int J Med Chem 2014;2014:395637.
9. Wolfe JF, Rathman TL, Sleevi MC, Campbell JA, Greenwood TD. Synthesis and anticonvulsant activity of some new 2-substituted 3-aryl-4(3H)-quinazolinones. J Med Chem 1990;33:161–6.
10. Rogawski MA, Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553–64.
11. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006;69:273–94.
12. Hayes BL. Microwave synthesis: chemistry at the speed of light. Matthews, NC: CEM Publishing; 2002.
13. Kappe CO, Dallinger D. The impact of microwave synthesis on drug discovery. Nat Rev Drug Discov 2006;5:51–63.
14. Armarego WLF. Quinazolines. Adv Heterocycl Chem 1963;1:253–309.
15. Auti PS, George G, Paul AT. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. RSC Adv 2020;10:41353–92.
16. Alexandre FR, Berecibar A, Besson T. Microwave-assisted Niementowski reaction. Back to the roots. Tetrahedron Lett 2002;43:3911–3.
17. Archana, Srivastava VK, Kumar A. Synthesis of newer thiadiazolyl and thiazolidinonyl quinazolin-4(3H)-ones as potential anticonvulsant agents. Eur J Med Chem 2002;37:873–82.

18. Jatav V, Mishra P, Kashaw S, Stables JP. CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1,3,4-thiadiazole-2-yl]-2-styryl quinazoline-4(3H)-ones. Eur J Med Chem 2008;43:1945–54.

19. Gedye R, Smith F, Westaway K, Ali H, Baldisera L, Laberge L, *et al.* The use of microwave ovens for rapid organic synthesis. Tetrahedron Lett 1986;27:279–82.

20. Giguere RJ, Bray TL, Duncan SM, Majetich G. Application of commercial microwave ovens to organic synthesis. Tetrahedron Lett 1986;27:4945–8.

21. Kappe CO. Microwave dielectric heating in synthetic organic chemistry. Chem Soc Rev 2008;37:1127–39.

22. Perreux L, Loupy A. A tentative rationalization of microwave effects in organic synthesis according to the reaction medium, and mechanistic considerations. Tetrahedron 2001;57:9199–223.

23. de la Hoz A, Díaz-Ortiz A, Moreno A. Microwaves in organic synthesis. Thermal and non-thermal microwave effects. Chem Soc Rev 2005;34:164–78.

24. Dudley GB, Richert R, Stiegman AE. On the existence of and mechanism for microwave-specific reaction rate enhancement. Chem Sci 2015;6:2144–52.

25. Kashaw SK, Kashaw V, Mishra P, Jain NK, Stables JP. Synthesis, anticonvulsant and CNS depressant activity of some new bioactive 1-(4-substituted-phenyl)-3-(4-oxo-2-phenyl/ethyl-4H-quinazolin-3-yl)-urea. Eur J Med Chem 2009;44:4335–43.

26. Varma RS. Solvent-free organic syntheses. Using supported reagents and microwave irradiation. Green Chem 1999;1:43–55.

27. Anastas PT, Warner JC. Green chemistry: theory and practice. New York: Oxford University Press; 1998.

28. Swinyard EA, Brown WC, Goodman LS. Comparative assays of antiepileptic drugs in mice and rats. J Pharmacol Exp Ther 1952;106:319–30.

29. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978;19:409–28.

30. Stables JP, Kupferberg HJ. The NIH Anticonvulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project. In: Avanzini G, Engel J, Fariello R, Heinemann U, editors. Molecular and cellular targets for antiepileptic drugs. London: John Libbey; 1997. p. 191–8.

31. Kehne JH, Klein BD, Raeissi S, Sharma S. The National Institute of Neurological Disorders and Stroke (NINDS) Epilepsy Therapy Screening Program (ETSP). Neurochem Res 2017;42:1894–903.

32. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011;20:359–68.

33. Rankovic Z. CNS drug design: balancing physicochemical properties for optimal brain exposure. J Med Chem 2015;58:2584–608.

34. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005;2:541–53.

35. Rudolph U, Möhler H. GABA-based therapeutic approaches: $GABA_A$ receptor subtype functions. Curr Opin Pharmacol 2006;6:18–23.